Breathable gas MRI could revolutionize CF lung monitoring

NCT ID NCT06339593

Recruiting now Knowledge-focused Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at new ways to measure lung changes in people with cystic fibrosis (CF) aged 12 to 21. Researchers will use a special MRI with a breathable gas called Xenon, along with a lung function test called LCI, to see how stopping or restarting airway clearance treatment affects the lungs. The goal is to find better, more sensitive tools to monitor CF lung disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hyperpolarized Xe129 gas (inhaled contrast agent for MRI)
What this could lead to: If successful, this could improve how doctors monitor lung health in cystic fibrosis, making it easier to detect early changes without invasive tests.
What could go wrong: This is an early-phase study with only 60 participants, so results may not apply to everyone. The new MRI techniques are still investigational and not yet FDA-approved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

Cincinnati Children's Hospital
RECRUITING

Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.